35 related news articles for Innate Immune Responses to Infection

Hudson Institute’s Director and CEO, Professor Elizabeth Hartland, is among the recipients of the Order of Australia in the King’s Birthday Honours list, for services to medical research.…  Read more

Every day we are reminded that women’s health conditions don’t receive the funding or priority in medical research that they should. Women are more likely to die from a heart attack, twice as likely to have a hip replacement fail (prosthetic hips have been developed for the male body), more likely to be over medicated (women are frequently excluded from clinical trials) and less likely to have their pain taken seriously.…  Read more

Hudson Institute’s reputation as a leader in inflammation research has been boosted by the appointment of two specialists in the field.…  Read more

Hudson Institute of Medical Research today officially unveiled its world-first RNAte platform that could see vaccines and therapeutic treatments developed faster by being able to rapidly assess their potential inflammation side effects, right here in Victoria.…  Read more

Director’s Message: Changing the odds on ovarian cancer. As medical researchers, we spend a lot of our time looking at numbers, establishing which changes or effects are significant and which are not.…  Read more

Hudson Institute has cemented its position among Australia’s medical research leaders, with Director and CEO, Professor Elizabeth Hartland becoming President of the peak industry body.…  Read more

Hudson Institute’s Research Committee has announced this year’s recipients of the Science Innovation Seed Funding Awards.…  Read more

Exciting new treatments for unmet medical needs including ovarian cancer have been awarded significant funding from Australia’s national biotechnology incubator, CUREator.…  Read more

The future of children with cancer is brighter today, with the announcement of significant funding from the Victorian government for paediatric cancer research.…  Read more

Director’s message: For children with cancer, change starts here. Childhood cancer is rare but devastating and new treatment options are desperately needed. In the last four decades the US Food and Drug Authority (FDA) has approved 500 drugs for adult cancers but just 12 to treat childhood cancers.…  Read more

A biomedical team based at Hudson Institute has received sought-after funding to pursue new international interdisciplinary RNA research cooperation.…  Read more

Hudson Institute’s Director and CEO, Professor Elizabeth Hartland, has been appointed the President Elect for the Association of Australian Medical Research Institutes (AAMRI). Professor Hartland will advance from her current roles as a member of the Board and the Chair of the Victorian branch of AAMRI, to take on the national leadership as President in 2023.…  Read more

This is the time of year when we look back at what we have achieved and acknowledge the people who helped us make it happen. …  Read more

It’s a disease that causes millions of deaths worldwide every year, but there are still large gaps in our understanding of what causes gastroenteritis.…  Read more

Welcome to Hudson News Winter 2022. As I write this, Mother’s Day is fast approaching and we look forward to celebrating and honouring our mothers as well as motherhood in all its forms.…  Read more

The CEO of Hudson Institute of Medical Research, Professor Elizabeth Hartland, has been appointed chair of the Victorian chapter of AAMRI, the Association of Australian Medical Research Institutes.…  Read more

It’s the essential physiological response that keeps you alive but can also kill you.…  Read more

Hudson Institute was proud to host the announcement of the Victorian Paediatric Cancer Consortium (VPCC).…  Read more

Hudson Institute has again been recognised as a leader in medical research with our CEO & Director appointed to the Council of the National Health and Medical Research Council (NHMRC).…  Read more

Hudson Institute of Medical Research is progressing its genomic and inflammation research with the acquisition of an Illumina NextSeq 2000, a new sequencing system that provides unprecedented genomic capacity to study inflammatory diseases and microbial diversity.…  Read more

It is unknown how US President Donald Trump will respond to the experimental immunotherapy given to treat his COVID-19 infection, because the drug has not yet been tested and approved, says Hudson Institute Director and CEO, Professor Elizabeth Hartland.…  Read more

Hudson Institute has received Victorian Government recognition under a workplace program encouraging healthy lifestyles.…  Read more

Hudson Institute has responded to the coronavirus outbreak (COVID-19) both scientifically and to protect the wellbeing of our staff and community.  Our world-leading scientists are applying their expertise in hyper-inflammation, to find ways to reduce the body’s overwhelming inflammatory response and acute respiratory distress that is leading to loss of lives from COVID-19. During this…  Read more

A two-day workshop is being held to promote collaborative research opportunities between cancer and inflammation researchers at Hudson Institute and the Department of Immunology at the University of Toronto.…  Read more

New and improved treatments for many serious ailments could follow a prestigious $5 million NHMRC Synergy grant to a team led by Hudson Institute of Medical Research scientists.…  Read more

Six Early Career Researchers have been chosen for the inaugural Hudson Institute Emerging Leaders program.…  Read more

Hudson Institute is delighted to announce the success of our researchers in the new NHMRC Investigator Grant round.…  Read more

Nine young women from secondary colleges in Melbourne’s southeast participated in a two-week immersive program at Hudson Institute that was funded as part of a concerted effort by the federal government to increase the number of women in science.…  Read more

More than 120 medical research scientists in the field of inflammation converged at Hudson Institute of Medical Research today to share knowledge and find solutions for patients across a broad range of diseases.…  Read more

A landmark Nature study that sheds light on how E.coli wreaks havoc on the body has earned Hudson Institute researcher, Dr Jaclyn Pearson, one of the nation’s top scientific awards. The National Association of Research Fellows (NARF) awarded Dr Pearson the 2018 Postdoctoral Investigator Award for her research that shows how some types of E.coli…  Read more

Ovarian cancer research leaders from across Australia met at Hudson Institute of Medical Research on Thursday, 15 November, for a new research symposium focused on progressing solutions to the disease.…  Read more

Two promising young Hudson Institute researchers, Dr Cristina Giogha and Aidan Kashyap received highly sought after Victoria Fellowships, funded by the State Government of Victoria and delivered by veski.…  Read more

Congratulations to the 2018 Hudson Institute Travel Awards recipients, who will attend international conferences and visiting laboratories to build invaluable knowledge in their area of research. The Awards (supported by donations from the Grisha Sklovsky Memorial Fund and Philip Wind Travel Fund) support six Hudson Institute Postdoctoral Fellows and PhD students to gain experience relevant…  Read more

Hudson Institute has had outstanding success in the recent NHMRC Project Grant round. In addition, our researchers have been awarded an NHMRC Partnership Grant, an NHMRC Development Grant, an ARC Discovery Grant and three NMHRC Fellowships.…  Read more

We are pleased to announce that Professor Elizabeth Hartland has accepted a position as the new Director and CEO of Hudson Institute of Medical Research. Professor Hartland obtained her BSc (Hons) majoring in Microbiology and Biochemistry and subsequently her PhD in Microbiology from the University of Melbourne.…  Read more